PBAC's latest decision on Dulaglutide: Recommended with restriction (2022). Considered for Treatment of type 2 diabetes. The submission concerns temporary supply of an overseas-sourced version to address shortage caused by increased demand due to semaglutide shortage.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
5
first 2017
Submissions
5
2017 → 2022
Eligible population
Patients with type 2 diabetes requiring dulaglutide treatment during supply shortage period.
Therapy area
Endocrinology
Line of therapy
Any
Evidence base
Cost-minimisation
Economic model
BIA only
ICER note
This is a minor submission for temporary listing of an alternative source product in response to supply shortage; no economic evaluation required.
Submission history
Nov 2017: Recommended with restriction · Authority Required
Nov 2019: Recommended with restriction · Authority Required
Jul 2020: Recommended with restriction · Authority Required
Mar 2022: Recommended with restriction · Authority Required
Oct 2022: Recommended with restriction · Restricted